Anticonvulsant activity of pregabalin in the maximal electroshock-induced seizure assay in α2δ1 (R217A) and α2δ2 (R279A) mouse mutants

Epilepsy Research

Volumn 108, Issue 5, 2014, Pages 833-842

  Lotarski, Susan ^a   Hain, Heather ^b   Peterson, Jason ^b   Galvin, Stacey ^b   Strenkowski, Bryan ^b   Donevan, Sean ^a   Offord, James ^a  

^a PFIZER INC   (United States)

^b EnVivo Pharmaceuticals Inc   (United States)

Author keywords

Genetically modified mice; Maximal electroshock; Pregabalin

Indexed keywords

ALANINE; ARGININE; PHENYTOIN; PREGABALIN; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED CALCIUM CHANNEL ALPHA2DELTA1 SUBUNIT; VOLTAGE GATED CALCIUM CHANNEL ALPHA2DELTA2 SUBUNIT; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; CACNA2D1 PROTEIN, MOUSE; CACNA2D2 PROTEIN, MOUSE; CALCIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG PROTEIN BINDING; ELECTRIC SHOCK; LATENT PERIOD; MOUSE; MOUSE MUTANT; MOUSE STRAIN; MUTATION; NONHUMAN; PRIORITY JOURNAL; SEIZURE; TREATMENT RESPONSE; WILD TYPE; 129 MOUSE; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; GENETICS; METABOLISM; MISSENSE MUTATION; PATHOPHYSIOLOGY; SEIZURES; SPECIES DIFFERENCE; TIME; TRANSGENIC MOUSE;

ANIMALS; ANTICONVULSANTS; CALCIUM CHANNELS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; GAMMA-AMINOBUTYRIC ACID; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION, MISSENSE; PHENYTOIN; SEIZURES; SPECIES SPECIFICITY; TIME FACTORS;

EID: 84900487650     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2014.03.002     Document Type: Article

References (39)

1. Bankstahl M., Müller C.J., Wilk E., Schughart K., Löscher W. Generation and characterization of pilocarpine-sensitive C57BL/6 mice as a model of temporal lobe epilepsy. Behav. Brain Res. 2012, 230(1):182-191. 10.1016/j.bbr.2012.02.004.
2. Barclay J., Balaguero N., Mione M., Ackerman S.L., Letts V.A., Brodbeck J., et al. Ducky mouse phenotype of epilepsy and ataxia is associated with mutations in the Cacna2d2 gene and decreased calcium channel current in cerebellar Purkinje cells. J. Neurosci. 2001, 21(16):6095-6104.
3. 2-δ protein. J. Med. Chem. 2005, 48(7):2294-2307. 10.1021/jm049762l.
4. Bian F., Li Z., Offord J., Davis M.D., McCormick J., Taylor C.P., Walker L.C. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res. 2006, 1075(1):68-80. 10.1016/j.brainres.2005.12.084.
5. Borowicz K.K., Stepień K., Czuczwar S.J. Fluoxetine Enhances the Anticonvulsant Effects of Conventional Antiepileptic Drugs in Maximal Electroshock Seizures. Pharmacological Reports: PR 2006, 58(1):83-90.
6. Brodbeck J., Davies A., Courtney J.M., Meir A., Balaguero N., Canti C., Moss F.J., Page K.M., Pratt W.S., Hunt S.P., Barclay J., Rees M., Dolphin A.C., et al. The ducky mutation in Cacna2d2 results in altered Purkinje cell morphology and is associated with the expression of a truncated alpha 2 delta-2 protein with abnormal function. Mult. Values Sel. 2001, 277(10):7684-7693. 10.1074/jbc.M109404200.
7. Castel-Branco M.M., Alves G.L., Figueiredo I.V., Falcao A.C., Caramona M.M. The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs. Methods Find. Exp. Clin. Pharmacol. 2009, 31(2):101. 10.1358/mf.2009.31.2.1338414.
8. Committee for the Update of the Guide for the Care and Use of Laboratory Animals National Research Council Guide for the care and use of laboratory animals 2011, The National Academies Press, Washington, DC. 8th ed.
9. Dolphin A.C. The effect of α2-δ and other accessory subunits on expression and properties of the calcium channel α1G. J. Physiol. (Lond.) 1999, 519:35-45. 10.1111/j.1469-7793.1999.0035o.x.
10. 2δ-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009, 139(2):380-392. 10.1016/j.cell.2009.09.025.
11. Ferraro T.N., Golden G.T., Smith G.G., DeMuth D., Buono R.J., Berrettini W.H. Mouse strain variation in maximal electroshock seizure threshold. Brain Res. 2002, 936(1-2):82-86.
12. Field M.J., Cox P.J., Stott E., Melrose H., Offord J., Su T.-Z., et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(46):17537-17542. 10.1073/pnas.0409066103.
13. Frankel W.N., Taylor L., Beyer B., Tempel B.L., White H.S. Electroconvulsive thresholds of inbred mouse strains. Genomics 2001, 74(3):306-312. 10.1006/geno.2001.6564.
14. 2δ subunit subtypes. J. Membr. Biol. 2001, 184(1):35-43. 10.1007/s00232-001-0072-7.
15. Hawkins N.A., Kearney J.A. Confirmation of an epilepsy modifier locus on mouse chromosome 11 and candidate gene analysis by RNA-Seq. Genes Brain Behav. 2012, 11(4):452-460. 10.1111/j.1601-183X.2012.00790.x.
16. Hendrich J., Van Minh A.T., Heblich F., Nieto-rostro M., Watschinger K., Striessnig J., et al. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(9):3628-3633. 10.1073/pnas.0708930105.
17. Hessel E.V.S., van Gassen K.L.I., Wolterink-Donselaar I.G., Stienen P.J., Fernandes C., Brakkee J.H., et al. Phenotyping mouse chromosome substitution strains reveal multiple QTLs for febrile seizure susceptibility. Genes Brain Behav. 2009, 8(2):248-255. 10.1111/j.1601-183X.2008.00466.x.
18. Holmes G.L. Animal model studies application to human patients. Neurology 2007, 69(24, Suppl. 3):S28-S32. 10.1212/01.wnl.0000302369.24230.c6.
19. Hosseinzadeh H., Nassiri Asl M. Anticonvulsant, sedative and muscle relaxant effects of carbenoxolone in mice. BMC Pharmacol. 2003, 3(1):3. 10.1186/1471-2210-3-3.
20. Kitano Y., Usui C., Takasuna K., Hirohashi M., Nomura M. Increasing-current electroshock seizure test: a new method for assessment of anti- and pro-convulsant activities of drugs in mice. J. Pharmacol. Toxicol. Methods 1996, 35(1):25-29.
21. Lander E.S., Schork N.J. Genetic dissection of complex traits. Science 1994, 265:2037-2048.
22. Lotarski S.M., Donevan S., El-Kattan A., Osgood S., Poe J., Taylor C.P., Offord J. Anxiolytic-like activity of pregabalin in the Vogel conflict test in alpha2delta-1 (R217A) and alpha2delta-2 (R279A) mouse mutants. J. Pharmacol. Exp. Ther. 2011, 338(2):615-621. 10.1124/jpet.111.180976.
23. Löscher W., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991, 8(2):79-94.
24. Office of Laboratory Animal Welfare National Institutes of Health Institutional Animal Care and Use Committee guidebook 2002, National Institutes of Health, Bethesda, MD. 2nd ed. M. Pitts (Ed.).
25. Rickels K., Pollack M.H., Feltner D.E., Lydiard R.B., Zimbroff D.L., Bielski R.J., et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch. Gen. Psychiatry 2005, 62(9):1022-1030. 10.1001/archpsyc.62.9.1022.
26. Rosenstock J., Tuchman M., LaMoreaux L., Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004, 110(3):628-638. 10.1016/j.pain.2004.05.001.
27. Sansig G., Bushell T.J., Clarke V.R., Rozov A., Burnashev N., Portet C., et al. Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7. J. Neurosci. 2001, 21(22):8734-8745.
28. Scudder C.L., Karczmar A.G., Everett G.M., Gibson J.E., Rifkin M. Brain catecholamines and serotonin levels in various strains and genera of mice and a possible interpretation for the correlations of amine levels with electroshock latency and behavior. Int. J. Neuropharmacol. 1966, 5(5):343-351.
29. Stahl S.M., Porreca F., Taylor C.P., Cheung R., Thorpe A.J., Clair A. The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?. Trends Pharmacol. Sci. 2013, 1-8. 10.1016/j.tips.2013.04.001.
30. Stefani A., Spadoni F., Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 1998, 37(1):83-91.
31. Sutton K.G., Martin D.J., Pinnock R.D., Lee K., Scott R.H. Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br. J. Pharmacol. 2002, 135(1):257-265. 10.1038/sj.bjp.0704439.
32. Taylor C.P., Garrido R. Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha2-delta (α2-δ) type 1 protein. Neuroscience 2008, 155(2):510-521. 10.1016/j.neuroscience.2008.05.053.
33. Thorpe A.J., Offord J. The alpha2-delta protein: an auxiliary subunit of voltage-dependent calcium channels as a recognized drug target. Curr. Opin. Invest. Drugs (Lond., Engl.: 2000) 2010, 11(7):761-770.
34. van Seventer R., Feister H.A., Young J.P., Stoker M., Versavel M., Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13 week, randomized trial. Curr. Med. Res. Opin. 2006, 22(2):375-384. 10.1185/030079906X80404.
35. Vartanian M.G., Radulovic L.L., Kinsora J.J., Serpa K.A., Vergnes M., Bertram E., Taylor C.P. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 2006, 68(3):189-205. 10.1016/j.eplepsyres.2005.11.001.
36. Welty D.F., Schielke G.P., Vartanian M.G., Taylor C.P. Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate. Epilepsy Res. 1993, 16(3):175-181.
37. White H.S. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 2003, 44(Suppl. 7):2-8.
38. White H.S., Johnson M., Wolf H.H., Kupferberg H.J. The early identification of anticonvulsant activity: role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models. Ital. J. Neurol. Sci. 1995, 16(1-2):73-77.
39. Winawer M.R., Kuperman R., Niethammer M., Sherman S., Rabinowitz D., Guell I.P., et al. Drug interactions with the newer antiepileptic drugs (AEDs)-Part 1: Pharmacokinetic and pharmacodynamic interactions between AEDs. Mamm. Genome 2007, 18(11):927-966. 10.1007/s00335-006-0087-6.